iFAST Diagnostics bags £5M to speed up infection testing and tackle antimicrobial resistance

2026-05-27 · Source: Tech.eu - Tech.eu · Field: Health & Wellbeing — Medical Devices & Health Technology, Pharmaceuticals & Biotechnology, Public Health & Epidemiology · Depth: Fundamental Awareness, quick

Summary

UK biotech iFAST Diagnostics has secured £5 million in a funding round led by Meridian Health Ventures, bringing its total investment to £12 million. This over-subscribed round, which included £2.1 million in non-dilutive loan funding from Innovate UK, values the company at almost five times its previous funding just 18 months ago. iFAST Diagnostics developed a rapid Antimicrobial Susceptibility Testing (AST) platform capable of delivering results in under three hours from a positive blood bottle or 3 to 4 hours from a raw urine sample. This significantly reduces the current standard process of over 40 hours, aiming to combat the \$4 billion (and growing) AST market by reducing treatment delays and slowing the spread of Antimicrobial Resistance (AMR). The new capital will facilitate UK rollout expansion, EU approval, and accelerate its US FDA regulatory program.

Key takeaway

For hospital administrators and infectious disease specialists aiming to improve patient outcomes and combat antimicrobial resistance, iFAST Diagnostics' rapid AST platform offers a critical solution. You should evaluate integrating such rapid testing systems to drastically cut diagnosis times from over 40 hours to under three, enabling faster, more targeted treatment decisions. This shift can significantly reduce the spread of drug-resistant infections and optimize resource allocation within your facility.

Key insights

iFAST Diagnostics' rapid AST platform significantly cuts infection testing time from over 40 hours to under three, combating antimicrobial resistance.

Principles

• Rapid diagnostics are crucial for AMR.
• Early, accurate testing improves patient outcomes.
• Non-dilutive funding can accelerate growth.

Method

The iFAST rapid AST system processes positive blood bottles in under three hours or raw urine samples in 3-4 hours, providing susceptibility results significantly faster than traditional methods.

In practice

• Implement rapid AST to reduce treatment delays.
• Explore non-dilutive funding for biotech scale-up.
• Prioritize EU/US regulatory approvals early.

Topics

• Antimicrobial Resistance
• Rapid Diagnostics
• Antimicrobial Susceptibility Testing
• Biotech Funding
• Clinical Microbiology
• FDA Approval

Best for: Investor, Entrepreneur, Domain Expert

Related on AIssential

• The hunt for the next antibiotics — Antimicrobial resistance threatens global health, necessitating urgent, diverse research into new antibiotics and resistance mitigation.
• ATUM’s New Lock-In™ Platform Solves Bispecific Mispairing — ATUM's Lock-In™ platform simplifies bispecific antibody development using an IgG-like architecture for enhanced stability and manufacturability.
• Tiny Graphene Drums Let Doctors Identify Bacteria by Sound — Graphene nanodrums can identify bacterial species and antibiotic resistance by analyzing their unique mechanical vibrations.
• AI-Native Healthcare: 100M Doctor Visits, 10–20 Hours Saved, Prior Auth in Minutes — Janie Lee & Chai Asawa, Abridge — Abridge transforms patient-clinician conversations into a clinical intelligence layer, enhancing care quality and operational efficiency.
• Benchmarking Machine Learning Architectures for Antimicrobial Stewardship in Pediatric ICUs — Machine learning performance for pediatric antimicrobial stewardship is driven more by target design and data characteristics than model complexity.
• Spotlight Pathology has raised £1.4M to catch blood cancer sooner — AI-powered image analysis can significantly improve the speed and consistency of blood cancer diagnosis.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.